Bayer: Strong growth, outlook elevated

Bayer: Strong growth, outlook elevated


Leverkusen, August four, 2022 – The Bayer Group realized substantial expansion in the second quarter of 2022. “We sent robust operational effectiveness. In terms of gross sales, we posted important gains at Crop Science and potent growth at Buyer Well being, as properly as a slight maximize at Prescription drugs, way too. And with EBITDA in advance of unique objects, we even accomplished growth of thirty percent,” said Werner Baumann, Chairman of the Board of Administration, on Thursday whilst presenting the company’s 50 %-calendar year economical report. “In check out of our fantastic business enterprise functionality and larger growth anticipations, we have lifted our entire-yr advice,” he stated.

Bayer does not currently see any substance fiscal impression in 2022 from any likely gasoline offer bottlenecks as a outcome of the war in Ukraine, Baumann stated. The corporation has taken techniques to guarantee that the direct affect of any possible gasoline shortages on its own manufacturing capabilities this year is contained to the best diploma achievable, he defined. “From a technological point of view, we are very well prepared to substantially decrease our reliance on normal fuel by switching to alternate and renewable sources of electricity. We have also launched applications to help save electricity and have built up our stocks of solutions wherever feasible.” A greater diploma of uncertainty stems from the company’s indirect publicity via its worldwide provider network, Baumann said. “That’s why we are growing our network of suppliers and making up additional inventory of important raw resources and packaging supplies.”

In the second quarter of 2022, Team sales enhanced by nine.6 percent to 12.819 billion euros on a currency- and portfolio-altered basis (Forex & portfolio adj.). EBITDA before unique merchandise superior by thirty.0 percent to three.349 billion euros. Optimistic forex effects benefited product sales by 915 million euros (Q2 2021: minus 524 million euros) and EBITDA prior to special items by three hundred million euros (Q2 2021: minus 153 million euros). EBIT came in at 169 million euros (Q2 2021: minus 2.281 billion euros) soon after web unique rates of 2.111 billion euros (Q2 2021: 3.901 billion euros) that generally comprised 1.322 billion euros in impairment losses on intangible belongings at the Crop Science Division. These impairment losses were being identified as aspect of impairment testing that was performed owing to a potent rise in money sector curiosity premiums. Other unique costs related to ongoing litigations and restructuring measures.

Bayer has taken an further provision of 694 million euros in the 2nd quarter largely due to ongoing settlement negotiations with the Condition of Oregon. The settlement, when finalized, would solve a pending environmental impairment situation, involving legacy Monsanto PCB products, and consequence in the dismissal of the scenario. Supplied the one of a kind difficulties, trial treatments, and substantive law for this case in this Oregon venue, the enterprise determined to pursue settlement, even though Monsanto voluntarily ceased creation of PCBs in 1977 and by no means disposed of the chemical in this condition. Bayer remains committed to protect long term scenarios through the litigation method. A short while ago, a Delaware Condition Court docket dismissed all of the state’s claims in a comparable PCB-related situation alleging environmental impairments.

Monsanto has broad indemnity agreements with its former buyers and the firm will pursue its rights to get better fees connected with the PCB-connected litigation. The company not long ago filed a criticism in the Circuit Courtroom of St. Louis County for the Point out of Missouri to implement its legal rights.

In the second quarter, internet money amounted to minus 298 million euros (Q2 2021: minus 2.335 billion euros), while core earnings for each share from continuing functions rose by 19.9 percent to 1.93 euros.

Cost-free hard cash flow was amount with the prior-yr period of time, at 1.a hundred and forty billion euros. Internet financial credit card debt as of June 30, 2022, came in at 36.575 billion euros, up five.9 percent from March 31, 2022.

Significantly enhanced market place ecosystem at Crop Science

In the agricultural business (Crop Science), Bayer amplified gross sales by 17.2 percent (Fx & portfolio adj.) to six.461 billion euros, pushed by a sizeable advancement in the marketplace natural environment. The division recorded double-digit percentage advancement in Latin America and Europe/Center East/Africa, and also registered an enlargement of organization in North The usa and Asia/Pacific. Herbicides posted the strongest progress, at fifty one.three % (Fx & portfolio adj.), with revenue rising specifically in Latin and North The us, as nicely as in Europe/Middle East/Africa as a outcome of selling prices for glyphosate-based mostly goods remaining higher. Income at Corn Seed & Features sophisticated by 9.five p.c (Forex & portfolio adj.), primarily owing to value will increase in North America, Europe/Middle East/Africa and Latin The us. In addition, volumes expanded in all areas besides North The united states. Sales at Fungicides rose by 4.3 per cent (Fx & portfolio adj.), with advancement in all areas besides North The us, where by volumes declined as a consequence of unfavorable weather conditions problems. Soybean Seed & Qualities noticed product sales drop by 16.1 percent (Forex & portfolio adj.), largely due to the major reduction in gross sales from overproduction in North The usa and the unit’s withdrawal from the Argentinian marketplace.

EBITDA prior to exclusive goods at Crop Science climbed by 71.8 percent to one.749 billion euros. The expansion in earnings was mostly pushed by the substantial advancement in small business functionality, as nicely as contributions from ongoing effectiveness programs. There was also a favourable forex result of 215 million euros (Q2 2021: minus 111 million euros). By contrast, earnings have been diminished by an increase in charges, significantly in the value of goods marketed, which was predominantly due to higher inflation. The EBITDA margin right before exclusive merchandise rose by six.8 percentage details to 27.1 per cent.

Productive product or service launches at Prescribed drugs

Profits of prescription medications (Prescribed drugs) amplified by two.1 percent (Forex & portfolio adj.) to four.818 billion euros. The division’s new goods, primarily Nubeqa™ and Kerendia™, continued their effective sector start, with income of the most cancers drug Nubeqa™ doubling when compared with the prior-year quarter. Even so, general income progress was held back again by extra tender processes in China, significantly for the most cancers drug Nexavar™ and the oral anticoagulant Xarelto™, which observed their international profits fall by 29.5 percent (Forex & portfolio adj.) and six.4 percent (Fx & portfolio adj.), respectively. Xarelto™ income had been also impacted by the expiration of the product’s patent in Brazil. By distinction, revenue of the ophthalmology drug Eylea™ rose by 11.7 percent (Fx & portfolio adj.), with enterprise up in all areas. The organization was capable to capture industry share, particularly in Europe, thanks in part to Eylea™ prefilled syringes. The division also registered substantial expansion for Adalat™, its coronary heart disorder treatment method, and Aspirin™ Cardio, its product or service for secondary avoidance of heart assaults. Gross sales of these two merchandise were being up eleven.2 percent (Forex & portfolio adj.) and 18.9 percent (Forex & portfolio adj.), respectively, because of to higher volumes in China. Income of the cancer drug Stivarga™ improved at an even stronger rate of 27.6 percent (Fx & portfolio adj.), mostly driven by expanded volumes in China and the United States.

EBITDA right before particular objects at Prescription drugs highly developed by 4.9 percent to 1.478 billion euros. Bigger raw content fees and elevated marketing investments in new solutions have been mostly offset by the progress in income. The division also produced profits from the sale of non-main companies. There had been positive currency results of 41 million euros (Q2 2021: minus 26 million euros). The EBITDA margin in advance of distinctive objects amounted to thirty.7 percent.

Purchaser Well being grows company in all regions

Bayer’s profits of self-treatment goods (Customer Overall health) sophisticated by 6.8 percent (Fx & portfolio adj.) to 1.496 billion euros, with wide-dependent progress in all locations and almost all groups. Sales in the Allergy & Cold group rose by 16.nine p.c (Fx & portfolio adj.), mostly owing to continually substantial chilly incidence rates in Europe and North The united states. In June, the division also started out providing Astepro™, a item that it switched from Rx to OTC status. As the initial and only steroid-totally free antihistamine nasal spray offered in excess of the counter on the U.S. market, Astepro™ is a differentiated, quick-operating option. Revenue rose by a double-digit share (Forex & portfolio adj.) in the Digestive Wellness class as perfectly, and the Dermatology and Discomfort & Cardio groups also recorded major expansion. Following publishing significant gains since 2020, product sales in the Nutritionals group declined by three.7 percent (Fx & portfolio adj.) but remained at a large degree overall.

EBITDA prior to exclusive products at Shopper Wellness climbed by 18.7 percent to 330 million euros. The expansion in earnings was on the back again of a robust rise in income, as properly as the division’s steady value and price management efforts in an environment of accelerating inflation. There ended up also good currency results of forty nine million euros (Q2 2021: minus 20 million euros). The EBITDA margin ahead of specific things rose by .5 percentage details to p.c.

Outlook for 2022 lifted

Adhering to the positive advancement of company in the 1st half of 2022, Bayer stays optimistic for the remainder of the year. It has as a result lifted its steerage for the Crop Science and Consumer Wellness divisions, and therefore also for the Group as a total.

On a forex-modified foundation (i.e. based mostly on the common month-to-month trade fees from 2021), Bayer now expects to generate profits of 47 billion to 48 billion euros in 2022 (formerly: approximately 46 billion euros). This now corresponds to an boost of about 8 percent (previously: close to 5 percent) on a currency- and portfolio-adjusted basis. The business is now targeting an EBITDA margin just before exclusive products of about 26 to 27 percent (beforehand: all around 26 percent) on a forex-altered foundation. Based mostly on the aforementioned sales figure, this would now correspond to EBITDA in advance of particular merchandise of about 12.5 billion euros (beforehand: all around twelve.0 billion euros) on a forex-modified basis. Core earnings for each share are now predicted to occur in at about 7.30 euros (previously: roughly seven.00 euros) on a currency-modified basis. Free of charge funds circulation is now forecast to sum to close to 2.5 billion euros (formerly: all-around 2 billion to two.5 billion euros) on a forex-modified basis. In addition, the organization carries on to hope year-close web economical financial debt of close to 33 billion to 34 billion euros on a forex-adjusted foundation. As in the total steerage, this figure does not get into account the contractually agreed divestment of the Environmental Science Skilled business.

Bayer has also geared up its steerage based on the closing trade premiums as of June 30, 2022and the variations to the forex-adjusted targets over are as follows: the firm now expects to make product sales of 50 billion to 51 billion euros (previously: about 47 billion euros). Based on the aforementioned revenue figure, Bayer is now focusing on EBITDA prior to special objects of all around 13.0 billion euros (beforehand: around 12. billion euros). Main earnings for each share are now envisioned to occur in at around 7.70 euros (earlier: close to seven.10 euros). In addition, the organization now expects calendar year-close internet financial debt of approximately 34 billion to 35 billion euros (previously: approximately 33 bill ion to 34 billion euros).

Sustainability: accessibility to revolutionary seeds and farming alternatives

Bayer also ongoing to make fantastic progress in terms of sustainability. The business is supporting the Zero Hunger Pledge, which will contain serving to smallholder farmers obtain ground breaking seeds, sustainable agricultural procedures and farming options, and thus furnishing them with new revenue-creating opportunities.

Bayer has also manufactured important development in a major ESG ranking: MSCI ESG Study a short while ago up to date their ESG Controversies Report and lifted the crimson flag relevant to “environmental concerns in excess of GMO crops” as nicely as their related allegation of a breach of the UN Worldwide Compact Ideas. This marks a further crucial milestone in bettering Bayer’s ESG rating profile.


The adhering to tables comprise the critical details for the Bayer Team and its divisions for the second quarter and the 1st 6 months of 2022.

The full 50 percent-yr fiscal report is accessible online at:

Extra information for traders and accessibility – from all-around 3 p.m. CEST – to the reside broadcast of the trader conference simply call at:

Print-top quality pictures can be found online

health Bayer-Critical-Data-Q2

Ahead-Wanting Statements

This launch might contain ahead-seeking statements based mostly on current assumptions and forecasts built by Bayer management. Many known and unknown challenges, uncertainties and other factors could guide to material dissimilarities amongst the genuine long term benefits, monetary scenario, improvement or functionality of the firm and the estimates supplied right here. These components contain those people talked about in Bayer’s public studies which are available on the Bayer web-site at The organization assumes no legal responsibility in anyway to update these ahead-on the lookout statements or to conform them to upcoming events or developments.

Read More

You May Also Like